Gan & Lee and Menarini Advance Bofanglutide in Europe
Beijing, China & Florence, Italy, September 3, 2026 Gan & Lee Pharmaceuticals and The Menarini Group have entered into...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Beijing, China & Florence, Italy, September 3, 2026 Gan & Lee Pharmaceuticals and The Menarini Group have entered into...
NAARDEN, The Netherlands; MIAMI, USA; and FLORENCE, Italy, July 24, 2026 NewAmsterdam Pharma and its commercialization partner Menarini Group...
SILVER SPRING, Maryland, June 12, 2026 The U.S. Food and Drug Administration (FDA) has cleared the Dexcom Stelo Glucose...
FLORENCE, Italy and NEW YORK, June 14, 2026 Menarini Group and its oncology-focused subsidiary Stemline Therapeutics have announced promising...
Florence, Italy – March 9, 2026 Menarini Group, one of Europe’s leading pharmaceutical companies, has reported strong financial growth...
